• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

RPB awards $4.8M in grants to supporteye research

Article

New York-Research to Prevent Blindness (RPB), announced 44 new grants totaling $4.8 million for investigations into the causes, treatment, and prevention of all blinding diseases.

New York-Research to Prevent Blindness (RPB), announced 44 new grants totaling $4.8 million for investigations into the causes, treatment, and prevention of all blinding diseases.

In the past 18 months, RPB has committed more than $12.9 million to eye research.

Across the United States, RPB-supported laboratories are investigating the entire spectrum of eye disease: from cataract, glaucoma, and diabetic reti-nopathy to age-related macular degeneration, retinitis pigmentosa, and eye movement disorders.

The latest awards were given to 29 medical institutions, including unrestricted and challenge grants to depart-ments of ophthalmology at 22 medical schools and 22 awards to individual scientists.

The recently-approved grant projects include:

Among RPB's vision scientists fighting eye diseases are nine active Jules and Doris Stein RPB Professors who receive $375,000 each over 5 years and up to $100,000 in a matching grant for laboratory construction.

An additional $150,000 may be awarded during a 2-year extension of the award.

RPB currently supports eye research at 54 medical institutions throughout the United States.

For a complete listing of grant recipients, go to http://www.rpbusa.org. OT

Related Videos
© 2024 MJH Life Sciences

All rights reserved.